Liposome-encapsulated hemoglobin transfusion rescues rats undergoing progressive hemodilution from lethal organ hypoxia without scavenging nitric oxide

Annals of Surgery

Volumn 248, Issue 2, 2008, Pages 310-319

  Nogami, Yashiro ^a   Kinoshita, Manabu ^a   Takase, Bonpei ^a   Ogata, Yoshitaka ^b   Saitoh, Daizoh ^a   Kikuchi, Makoto ^c   Ishihara, Masayuki ^a   Maehara, Tadaaki ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b National Defense Medical College   (Japan)

^c Terumo Research Institute   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPOSOME; NITRIC OXIDE;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD COMPONENT; BLOOD TRANSFUSION; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; ENCAPSULATION; ENDOTHELIUM; ERYTHROCYTE COUNT; FLUID RESUSCITATION; HEART INJURY; HEMODILUTION; HEMORRHAGIC SHOCK; HYPOXIA; KIDNEY INJURY; LIPID BILAYER; LIVER INJURY; MALE; MAMMAL; METABOLIC ACIDOSIS; NEUROENDOCRINE SYSTEM; NONHUMAN; OXYGEN CONSUMPTION; OXYGEN TRANSPORT; PRIORITY JOURNAL; RAT; VASOCONSTRICTION; ANIMAL; ANOXIA; BLOOD; BLOOD COMPONENT THERAPY; CHEMISTRY; DISEASE MODEL; FLUID THERAPY; HEART STROKE VOLUME; KIDNEY; LIVER; LUNG; LUNG LAVAGE; METABOLISM; METHODOLOGY; MICROCAPSULE; MULTIPLE ORGAN FAILURE; NONPARAMETRIC TEST; ORGAN SIZE; PATHOLOGY; RANDOMIZATION; RESUSCITATION; SPRAGUE DAWLEY RAT; SURVIVAL; VASCULARIZATION;

ANIMALS; ANOXIA; BLOOD COMPONENT TRANSFUSION; BRONCHOALVEOLAR LAVAGE FLUID; CAPSULES; DISEASE MODELS, ANIMAL; FLUID THERAPY; HEMODILUTION; HEMOGLOBINS; KIDNEY; LIPOSOMES; LIVER; LUNG; MALE; MULTIPLE ORGAN FAILURE; NITRIC OXIDE; ORGAN SIZE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RESUSCITATION; SHOCK, HEMORRHAGIC; STATISTICS, NONPARAMETRIC; STROKE VOLUME; SURVIVAL ANALYSIS;

EID: 49849098721     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181820c80     Document Type: Article

References (47)

1. Przybelski RJ, Malcolm DS, Burris DG, et al. Cross-linked hemoglobin solution as a resuscitative fluid after hemorrhage in the rat. J Lab Clin Med. 1991;117:143-151.
2. Schultz SC, Powell CC, Burris DG, et al. The efficacy of diaspirin crosslinked hemoglobin solution resuscitation in a model of uncontrolled hemorrhage. J Trauma. 1994;37:408-412.
3. Sloan EP, Koenigsberg M, Gens D, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. Jama. 1999;282:1857-1864.
4. Handrigan MT, Bentley TB, Oliver JD, et al. Choice of fluid influences outcome in prolonged hypotensive resuscitation after hemorrhage in awake rats. Shock. 2005;23:337-343.
5. Gould SA, Moore EE, Hoyt DB, et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg. 1998;187:113-120, discussion 120 -122.
6. Moore EE, Cheng AM, Moore HB, et al. Hemoglobin-based oxygen carriers in trauma care: scientific rationale for the us multicenter prehospital trial. World J Surg. 2006;30:1247-1257.
7. Schultz SC, Grady B, Cole F, et al. A role for endothelin and nitric oxide in the pressor response to diaspirin cross-linked hemoglobin. J Lab ClinMed. 1993;122:301-308.
8. Doherty DH, Doyle MP, Curry SR, et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol. 1998;16:672-676.
9. Tsai AG, Vandegriff KD, Intaglietta M, Winslow RM. Targeted O2 delivery by low-P50 hemoglobin: a new basis for O2 therapeutics. Am J Physiol Heart Circ Physiol. 2003;285:H1411-H1419.
10. Vandegriff KD, Malavalli A, Wooldridge J, et al. MP4, a new nonva- soactive PEG-Hb conjugate. Transfusion. 2003;43:509-516.
11. Bjorkholm M, Fagrell B, Przybelski R, et al. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol. Haematologica. 2005;90:505-515.
12. Ogata Y, Goto H, Kimura T, Fukui H. Development of neo red cells (NRC) with the enzymatic reduction system of methemoglobin. Artif Cells Blood Substit Immobil Biotechnol. 1997;25:417-427.
13. Sakai H, Takeoka S, Park SI, et al. Surface modification of hemoglobin vesicles with poly(ethylene glycol) and effects on aggregation, viscosity, and blood flow during 90% exchange transfusion in anesthetized rats. Bioconjug Chem. 1997;8:23-30.
14. Sakai H, Horinouchi H, Tomiyama K, et al. Hemoglobin-vesicles as oxygen carriers: influence on phagocytic activity and histopathological changes in reticuloendothelial system. Am J Pathol. 2001;159:1079-1088.
15. Oda T, Nakajima Y, Kimura T, et al. Hemodilution with liposome- encapsulated low-oxygen-affinity hemoglobin facilitates rapid recovery from ischemic acidosis after cerebral ischemia in rats. J ArtifOrgans. 2004;7:101-106.
16. Oda T, Kimura T, Ogata Y, Fujise Y. Hemodilution with liposome- encapsulated low-oxygen-affinity hemoglobin does not attenuate hypo- thermic cerebral ischemia in rats. J ArtifOrgans. 2005;8:263-269.
17. Sakai H, Masada Y, Horinouchi H, et al. Hemoglobin-vesicles suspended in recombinant human serum albumin for resuscitation from hemorrhagic shock in anesthetized rats. Crit Care Med. 2004;32:539-545.
18. Sakai H, Tomiyama K, Masada Y, et al. Pretreatment of serum containing hemoglobin vesicles (oxygen carriers) to prevent their interference in laboratory tests. Clin Chem Lab Med. 2003;41:222-231.
19. Ishibashi T, Kubota K, Himeno M, et al. Respiratory alkalosis does not alter NOx concentrations in human plasma and erythrocytes. Am J Physiol Heart Circ Physiol. 2001;281:H2757-H2761.
20. Ishibashi T, Yoshida J, Nishio M. New methods to evaluate endothelial function: A search for a marker of nitric oxide (NO) in vivo: re- evaluation of NOx in plasma and red blood cells and a trial to detect nitrosothiols. J Pharmacol Sci. 2003;93:409-416.
21. Ishibashi T, Matsubara T, Ida T, et al. Negative NO3- difference in human coronary circulation with severe atherosclerotic stenosis. Life Sci. 2000;66:173-184.
22. Boluyt MO, Converso K, Hwang HS, et al. Echocardiographic assess-ment of age-associated changes in systolic and diastolic function of the female F344 rat heart. J Appl Physiol. 2004;96:822-828.
23. Kinoshita M, Ono S, Mochizuki H. Neutrophils mediate acute lung injury in rabbits: role of neutrophil elastase. Eur Surg Res. 2000;32: 337-346.
24. Kinoshita M, Seki S, Ono S, et al. Paradoxical effect of IL-18 therapy on the severe and mild Escherichia coli infections in burn-injured mice. Ann Surg. 2004;240:313-320.
25. Szebeni J, Fontana JL, Wassef NM, et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation. 1999;99:2302-2309.
26. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92:5510-5514.
27. Semenza GL. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol. 2000;59:47-53.
28. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia- inducible factor 1. Annu Rev Cell Dev Biol. 1999;15:551-578.
29. Ellis G, Adatia I, Yazdanpanah M, Makela SK. Nitrite and nitrate analyses: a clinical biochemistry perspective. Clin Biochem. 1998;31:195-220.
30. Phillips WT, Klipper RW, Awasthi VD, et al. Polyethylene glycol- modified liposome-encapsulated hemoglobin: a long circulating red cell substitute. Pharmacol Exp Ther. 1999;288:665-670.
31. Sakai H, Tomiyama KI, Sou K, et al. Poly(ethylene glycol)-conjugation and deoxygenation enable long-term preservation of hemoglobin-vesicles as oxygen carriers in a liquid state. Bioconjug Chem. 2000;11:425-432.
32. Standl T, Burmeister MA, Horn EP, et al. Bovine haemoglobin-based oxygen carrier for patients undergoing haemodilution before liver resection. Br J Anaesth. 1998;80:189-194.
33. LaMuraglia GM, O'Hara PJ, Baker WH, et al. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin- based solution. J Vasc Surg. 2000;31:299-308.
34. Levy JH, Goodnough LT, Greilich PE, et al. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J Thorac Cardiovasc Surg. 2002;124:35-42.
35. Hughes GS Jr, Antal EJ, Locker PK, et al. Physiology and pharmaco-kinetics of a novel hemoglobin-based oxygen carrier in humans. Crit Care Med. 1996;24:756-764.
36. Kasper SM, Walter M, Grune F, et al. Effects of a hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth Analg. 1996;83:921-927.
37. Levien LJ. South Africa: clinical experience with Hemopure. ISBT Science Series (2006). 2006;1:167-173.
38. Johnson JL, Moore EE, Offner PJ, et al. Resuscitation of the injured patient with polymerized stroma-free hemoglobin does not produce systemic or pulmonary hypertension. Am JSurg. 1998;176:612-617.
39. Johnson JL, Moore EE, Offner PJ, et al. Resuscitation with a blood substitute abrogates pathologic postinjury neutrophil cytotoxic function. J Trauma. 2001;50:449-455, discussion 456.
40. Gould SA, Moore EE, Hoyt DB, et al. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. JAm Coll Surg. 2002;195:445-452, discussion 452-455.
41. Torres Filho IP, Spiess BD, Barbee RW, et al. Systemic responses to hemodilution after transfusion with stored blood and with a hemoglobin- based oxygen carrier. Anesth Analg. 2005;100:912-920.
42. Cheng DC, Mazer CD, Martineau R, et al. A phase II dose-response study of hemoglobin raffimer (Hemolink) in elective coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2004;127:79-86.
43. Young MA, Riddez L, Kjellstrom BT, et al. MalPEG-hemoglobin (MP4) improves hemodynamics, acid-base status, and survival after uncontrolled hemorrhage in anesthetized swine. Crit Care Med. 2005;33: 1794-1804.
44. Olofsson C, Ahl T, Johansson T, et al. A multicenter clinical study ofthe safety and activity of maleimide-polyethylene glycol-modified Hemoglobin (Hemospan) in patients undergoing major orthopedic surgery. Anesthesiology. 2006;105:1153-1163.
45. Sakai H, Takeoka S, Wettstein R, et al. Systemic and microvascular responses to hemorrhagic shock and resuscitation with Hb vesicles. Am J Physiol Heart Circ Physiol. 2002;283:H1191-H1199.
46. Nathens AB. Massive transfusion as a risk factor for acute lung injury: association or causation? Crit Care Med. 2006;34(5 Suppl):S144-S150.
47. Sakai H, Horinouchi H, Yamamoto M, et al. Acute 40 percent exchange- transfusion with hemoglobin-vesicles (HbV) suspended in recombinant human serum albumin solution: degradation of HbV and erythropoiesis in a rat spleen for 2 weeks. Transfusion. 2006;46:339-347.